中间型、后部或全葡萄膜炎患者随机接受氟轻松玻璃体内植入剂或全身治疗后长达10年随访中继发性青光眼的发病率与结局
该研究为多中心葡萄膜炎类固醇治疗(MUST)临床试验队列的前瞻性随访,纳入232例中间型、后部或全葡萄膜炎患者共405只患眼,随机分配至氟轻松玻璃体内植入剂(0.59 mg)或全身治疗组。在112只发生青光眼的患眼中,诊断后5年内持续平均偏差恶化≥6 dB的累积发生率为20%,视杯视盘比持续恶化≥0.2的累积发生率为26%。结论认为植入剂治疗青光眼风险显著高于全身治疗,且不能完全由治疗后眼压升高解释。
要点
- 发生青光眼的患眼中,5年内持续平均偏差恶化≥6 dB的累积发生率为20%,视杯视盘比恶化≥0.2的累积发生率为26%。
核心结论
- 氟轻松玻璃体内植入剂治疗中间型、后部或全葡萄膜炎的青光眼风险显著高于全身治疗,且该差异不能完全由治疗后眼压升高解释。
- 多数病例通过眼压管理可有效预防青光眼恶化,但即使在专家临床管理下,部分青光眼仍会进展。
- 葡萄膜炎患者应无限期仔细监测眼压和青光眼。
研究设计与样本
- 多中心葡萄膜炎类固醇治疗(MUST)临床试验队列的前瞻性随访。
- 纳入232例中间型、后部或全葡萄膜炎患者共405只患眼,随机分配至氟轻松玻璃体内植入剂(0.59 mg)或全身治疗(>90%接受皮质类固醇联合免疫抑制治疗)。
- 中位随访时间为6.9年。
主要发现
- 在112只发生青光眼的患眼中,诊断后5年内持续平均偏差恶化≥6 dB的累积发生率为20%(95%CI 12%-33%)。
- 5年内持续视杯视盘比恶化≥0.2的累积发生率为26%(95%CI 17%-39%)。
关键数值与推荐
- 持续平均偏差恶化≥6 dB的5年累积发生率为20%(95%CI 12%-33%)。
- 持续视杯视盘比恶化≥0.2的5年累积发生率为26%(95%CI 17%-39%)。
临床怎么用
- 对接受氟轻松玻璃体内植入剂治疗的葡萄膜炎患者,应加强眼压和青光眼监测。
- 葡萄膜炎患者无论接受何种治疗,均需长期甚至无限期监测眼压和青光眼。
- 眼压升高管理对多数患者可有效预防青光眼恶化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate long-term risk and outcomes of glaucoma in eyes with intermediate, posterior, and panuveitis managed with systemic or fluocinolone acetonide (0.59 mg, "implant") therapy. DESIGN: Prospective Follow-up of the Multicenter Uveitis Steroid Treatment (MUST) Clinical Trial Cohort. METHODS: Patients with intermediate, posterior, or panuveitis randomized to implant or systemic therapy (corticosteroid plus immunosuppression in >90%) were followed prospectively for glaucoma incidence and outcome. RESULTS: Among 405 uveitic at-risk eyes of 232 patients (median follow-up = 6.9 years), 40% (79/196) of eyes assigned and treated with implant and 8% (17/209) of eyes assigned and treated with systemic therapy (censoring eyes receiving an implant on implantation) developed glaucoma (hazard ratio [HR] = 5.9, 95% confidence interval [CI] 3.2, 10.8; P < .001). Adjustment for intraocular pressure (IOP) elevation during follow-up only partially mitigated the association of implant treatment with glaucoma incidence: HR = 3.1 (95% CI 1.6, 6.0); P = .001. Among 112 eyes of 83 patients developing glaucoma, the 5-year cumulative incidence following diagnosis of sustained (2 or more consecutive visits) worsening of mean deviation by ≥6 dB was 20% (95% CI 12%, 33%); 5-year cumulative incidence of sustained worsening of cup-to-disc ratio by ≥0.2 was 26% (95% CI 17%, 39%). CONCLUSIONS: The implant has substantially higher risk of glaucoma than systemic therapy, a difference not entirely explained by posttreatment IOP elevation. Management of IOP elevation was effective in preventing worsening of glaucoma for the large majority of cases, but even under expert clinical management, some glaucoma worsened. Uveitis cases should be monitored carefully for IOP elevation and glaucoma indefinitely.
引用
- Kempen JH, Van Natta ML, Friedman DS, et al. Incidence and Outcome of Uveitic Glaucoma in Eyes With Intermediate, Posterior, or Panuveitis Followed up to 10 Years After Randomization to Fluocinolone Acetonide Implant or Systemic Therapy. Am J Ophthalmol. 2020. PMID: 32628922. doi:10.1016/j.ajo.2020.06.038
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。